Kaveri Pohlman
Stock Analyst at Clear Street
(4.33)
# 1,350
Out of 4,707 analysts
225
Total ratings
40.5%
Success rate
11.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Maintained: Buy | $99 | $40.38 | +145.17% | 3 | Sep 8, 2026 | |
| JBIO Jade Biosciences | Rated: Buy | $25 → $48 | $19.45 | +146.79% | 3 | Sep 4, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $173 | $145.94 | +18.54% | 7 | Aug 31, 2026 | |
| LBRX LB Pharmaceuticals | Rated: Buy | $45 → $69 | $49.39 | +39.70% | 2 | Aug 21, 2026 | |
| CGEM Cullinan Therapeutics | Rated: Buy | $46 → $47 | $21.69 | +116.69% | 20 | Aug 14, 2026 | |
| ELVN Enliven Therapeutics | Rated: Buy | $55 → $68 | $59.37 | +14.54% | 3 | Aug 6, 2026 | |
| EQ Equillium | Maintained: Buy | $9 | $2.41 | +273.44% | 2 | Aug 3, 2026 | |
| EVMN Evommune | Maintained: Buy | $28 | $13.08 | +114.07% | 3 | Jul 16, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $14.94 | +368.54% | 6 | Jun 22, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $10.71 | +161.44% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 → $29 | $16.82 | +72.41% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $533 → $680 | $534.16 | +27.30% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 → $131 | $94.31 | +38.90% | 4 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $2.20 | +445.45% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $16.28 | +22.85% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $152.28 | +44.47% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $20.04 | -40.12% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.44 | +90.68% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $6.13 | +193.64% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.61 | +81.54% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $30.28 | +55.22% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $57.67 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.32 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.33 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.06 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $33.53 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.77 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.50 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.89 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $2.51 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.65 | n/a | 3 | Jul 6, 2022 |
Structure Therapeutics
Sep 8, 2026
Maintained: Buy
Price Target: $99
Current: $40.38
Upside: +145.17%
Jade Biosciences
Sep 4, 2026
Rated: Buy
Price Target: $25 → $48
Current: $19.45
Upside: +146.79%
Protagonist Therapeutics
Aug 31, 2026
Maintained: Buy
Price Target: $173
Current: $145.94
Upside: +18.54%
LB Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $45 → $69
Current: $49.39
Upside: +39.70%
Cullinan Therapeutics
Aug 14, 2026
Rated: Buy
Price Target: $46 → $47
Current: $21.69
Upside: +116.69%
Enliven Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $59.37
Upside: +14.54%
Equillium
Aug 3, 2026
Maintained: Buy
Price Target: $9
Current: $2.41
Upside: +273.44%
Evommune
Jul 16, 2026
Maintained: Buy
Price Target: $28
Current: $13.08
Upside: +114.07%
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $70
Current: $14.94
Upside: +368.54%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $10.71
Upside: +161.44%
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $16.82
Upside: +72.41%
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $534.16
Upside: +27.30%
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $94.31
Upside: +38.90%
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $2.20
Upside: +445.45%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $16.28
Upside: +22.85%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $152.28
Upside: +44.47%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $20.04
Upside: -40.12%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.44
Upside: +90.68%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $6.13
Upside: +193.64%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $6.61
Upside: +81.54%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $30.28
Upside: +55.22%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $57.67
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.32
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $25.33
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $29.06
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $33.53
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $14.77
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $6.50
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.89
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $2.51
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.65
Upside: n/a